Hospital

During a 15-year period, 1 in 5 older adults living with COPD received a shingles vaccine.

Pelabresib is an investigational, oral, small molecule that inhibits bromodomain and extraterminal (BET) proteins.

The data support the use of supportive anemia care agents in combination with ruxolitinib (Jakafi; Incyte Corp).

The authors suggest that targeted interventions to mitigate financial toxicity should be implemented to better support patients.

Zenocutuzumab-zbco is a bispecific antibody that targets and binds to HER2 and HER3.

The management of MDS is primarily targeted at controlling or slowing the disease and preventing future complications as much as possible.

The decline was attributed to continued adherence to infection prevention and control measures.

Metabolic bariatric surgery rates has decreased in response to increased use of glucagon-like peptide-1 (GLP-1) receptor agonists.

Anemia is a very common adverse effect associated with the use of ruxolitinib.

Key trends shaping the future of health-system pharmacy include advanced medication management to address supply chain challenges, digital transformation to enhance pharmacy operations, and strategies for compliance with evolving regulations, all of which will be central topics at the ASHP Midyear 2024 meeting.

Clinicians' enthusiasm for cell and gene therapies is tempered by practical concerns.

These risks were observed to become higher as gestational age decreased.

The study also found that HSSPs minimize health costs and provide additional revenue for health systems.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses a study she conducted that highlights how social determinants of health exacerbate severity and increase rates of mortality from Clostridioides difficile infections in vulnerable communities.

Investigators say basic immunodeficiency screening should be completed in full for this patient population.

The therapy has similar benefits for both older and younger patients with multiple myeloma.

The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.

AI-enabled remote cardiac telemetry can help manage stress’s effects on high-risk populations.

The pharmacist’s role includes determining if there are any medications that are contributing to magnesium deficiency for patients with diabetes who are at an increased risk.

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.

The addition of navitoclax was associated with durable response and potential disease modification.

Pneumococcal disease incidence decreased in adults after pneumococcal vaccines began to be used in children due to indirect protection, with fewer adults found to carry the bacterium that causes disease.

Researchers developed a method to stabilize respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) fusion (F) proteins, advancing potential vaccines for both viruses.

Knowledge of recent intravenous immunoglobulin (IVIG) administration in patients receiving the common laboratory test can help inform misdiagnosis.

In trials, blood pressure reductions were maintained over extended periods, suggesting that the drug could offer a sustained effect.

Methemoglobinemia is a blood disorder that affects proper release of oxygen around the body.

Trends across small cell lung cancer (SCLC) and diffuse large B-cell lymphoma (DLBCL) emphasize the need to further improve global treatment options.

The approval is based on clinical studies that demonstrate the management of heart rate with minimal reductions to blood pressure.

Lisocabtagene maraleucel chimeric antigen receptor T-cell therapy significantly enhances treatment of relapsed/refractory B-cell malignancies, offering high response rates and durable remissions.